The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Real world data for axi-cel in lymphoma with secondary CNS involvement
In the ZUMA-1 trial leading to the FDA approval of axicabtagene ciloleucel (axi-cel), patients with prior or active secondary central nervous system (CNS) lymphoma involvement were excluded. However, understanding the outcomes of axi-cel in this setting is important. Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the results from the US Lymphoma CAR-T Consortium real world experience in patients treated with axi-cel who had a history of secondary CNS involvement or had active CNS disease at time of CAR-T infusion. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
